IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-48327-9.html
   My bibliography  Save this article

1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma

Author

Listed:
  • Travis S. Johnson

    (Indiana University
    Indiana Biosciences Research Institute
    Indiana University
    Indiana University)

  • Parvathi Sudha

    (Indiana University)

  • Enze Liu

    (Indiana University)

  • Nathan Becker

    (Indiana University)

  • Sylvia Robertson

    (Indiana Biosciences Research Institute)

  • Patrick Blaney

    (New York University)

  • Gareth Morgan

    (New York University)

  • Vivek S. Chopra

    (Genentech Inc.)

  • Cedric Santos

    (Genentech Inc.)

  • Michael Nixon

    (Roche Inc.)

  • Kun Huang

    (Indiana University
    Indiana University
    Indiana University)

  • Attaya Suvannasankha

    (Indiana University
    Roudebush VAMC)

  • Mohammad Abu Zaid

    (Indiana University)

  • Rafat Abonour

    (Indiana University)

  • Brian A. Walker

    (Indiana University
    Indiana University)

Abstract

Multiple Myeloma is an incurable plasma cell malignancy with a poor survival rate that is usually treated with immunomodulatory drugs (iMiDs) and proteosome inhibitors (PIs). The malignant plasma cells quickly become resistant to these agents causing relapse and uncontrolled growth of resistant clones. From whole genome sequencing (WGS) and RNA sequencing (RNA-seq) studies, different high-risk translocation, copy number, mutational, and transcriptional markers can be identified. One of these markers, PHF19, epigenetically regulates cell cycle and other processes and is already studied using RNA-seq. In this study, we generate a large (325,025 cells and 49 patients) single cell multi-omic dataset and jointly quantify ATAC- and RNA-seq for each cell and matched genomic profiles for each patient. We identify an association between one plasma cell subtype with myeloma progression that we call relapsed/refractory plasma cells (RRPCs). These cells are associated with chromosome 1q alterations, TP53 mutations, and higher expression of PHF19. We also identify downstream regulation of cell cycle inhibitors in these cells, possible regulation by the transcription factor (TF) PBX1 on chromosome 1q, and determine that PHF19 may be acting primarily through this subset of cells.

Suggested Citation

  • Travis S. Johnson & Parvathi Sudha & Enze Liu & Nathan Becker & Sylvia Robertson & Patrick Blaney & Gareth Morgan & Vivek S. Chopra & Cedric Santos & Michael Nixon & Kun Huang & Attaya Suvannasankha &, 2024. "1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
  • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-48327-9
    DOI: 10.1038/s41467-024-48327-9
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-48327-9
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-024-48327-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Stephan M. Tirier & Jan-Philipp Mallm & Simon Steiger & Alexandra M. Poos & Mohamed H. S. Awwad & Nicola Giesen & Nicola Casiraghi & Hana Susak & Katharina Bauer & Anja Baumann & Lukas John & Anja Sec, 2021. "Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics," Nature Communications, Nature, vol. 12(1), pages 1-16, December.
    2. Rebecca Boiarsky & Nicholas J. Haradhvala & Jean-Baptiste Alberge & Romanos Sklavenitis-Pistofidis & Tarek H. Mouhieddine & Oksana Zavidij & Ming-Chieh Shih & Danielle Firer & Mendy Miller & Habib El-, 2022. "Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Aleksandrina Goeva & Michael-John Dolan & Judy Luu & Eric Garcia & Rebecca Boiarsky & Rajat M. Gupta & Evan Macosko, 2024. "HiDDEN: a machine learning method for detection of disease-relevant populations in case-control single-cell transcriptomics data," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
    2. David G. Coffey & Francesco Maura & Edgar Gonzalez-Kozlova & J. Javier Diaz-Mejia & Ping Luo & Yong Zhang & Yuexin Xu & Edus H. Warren & Travis Dawson & Brian Lee & Hui Xie & Eric Smith & Amanda Ciard, 2023. "Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    3. Lukas John & Alexandra M. Poos & Alexander Brobeil & Carolina Schinke & Stefanie Huhn & Nina Prokoph & Raphael Lutz & Barbara Wagner & Maurizio Zangari & Stephan M. Tirier & Jan-Philipp Mallm & Sabrin, 2023. "Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    4. Aleksandr Ianevski & Kristen Nader & Kyriaki Driva & Wojciech Senkowski & Daria Bulanova & Lidia Moyano-Galceran & Tanja Ruokoranta & Heikki Kuusanmäki & Nemo Ikonen & Philipp Sergeev & Markus Vähä-Ko, 2024. "Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones," Nature Communications, Nature, vol. 15(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-48327-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.